Skip to main content

Call for papers

Prevention and Early Diagnosis of Breast Cancer

We are welcoming submissions to our new collection on prevention and early diagnosis of breast cancer, guested edited by Monica Pernia Marin, Caren Greenstein, and Mary Salvatore.

Submission Deadline:
27 February 2025

Molecular mimicry in human diseases

We are welcoming submissions to our new collection on molecular mimicry in human diseases, guested edited by Luigi Buonaguro and Jamie Rossjohn.

Submission Deadline:
15 December 2024

Planeterranean Diet

Submit to our new collection, "Planeterranean" Diet: Globally Extending the Health Benefits of the Mediterranean Diet, guest edited by Luigi Barrea, Salvatore Nesci, Prisco Piscitelli, Laura Soldati, and Claudia Vetrani.

Submission Deadline: 30 June 2024

Article Collections

Fibrosis and Cancer Intersection

Edited by Dr Mary Salvatore &
Dr Monica Pernia

Top trending articles

Check out the most discussed articles from the previous month!

Meet the Editors

Get to know the Editors behind Journal of Translational Medicine! 


Featured Research: Multiomics analysis identifies oxidative phosphorylation as a cancer vulnerability arising from myristoylation inhibition

In humans, two ubiquitously expressed N-myristoyltransferases, NMT1 and NMT2, catalyze myristate transfer to proteins to facilitate membrane targeting and signaling. We investigated the expression of NMTs in numerous cancers and found that NMT2 levels are dysregulated by epigenetic suppression, particularly so in hematologic malignancies. This suggests that pharmacological inhibition of the remaining NMT1 could allow for the selective killing of these cells, sparing normal cells with both NMTs. Targeting of both, oxidative phosphorylation and cell signaling partly explains the lethal effects of zelenirstat in select cancer types. Our findings continue to warrant the clinical development of zelenirstat as cancer treatment.

Featured Review: Mechanism of action, potency and efficacy: considerations for cell therapies

One of the most challenging aspects of developing advanced cell therapy products (CTPs) is defining the mechanism of action (MOA), potency and efficacy of the product. This perspective examines these concepts and presents helpful ways to think about them through the lens of metrology. MOA, potency, potency test, efficacy, efficacy endpoint and efficacy endpoint tests should be independently defined to improve clarity during discussions concerning correlations between potency test results and clinical outcomes. The ideas and observations presented herein may be helpful to product developers for setting realistic goals for understanding a product’s MOA and for establishing correlations between potency tests and clinical efficacy.

Journal of Translational Medicine has launched In Review, a new option that provides authors with on-demand information on the status of their manuscript, enables them to share their work with funders and their research community, and allows their colleagues to comment and collaborate - all whilst their manuscript is under review.

Read More

Featured section: Neuroscience

The Neuroscience section aims to encourage publications that help to reduce the gap between basic preclinical science and medical applications for the patients in the neuroscience field. Any new tool for the dissemination of results in the field can greatly help to progress in the new solutions for the neuropsychiatric patient. The section aims to promote the increase of knowledge on the subject by publishing original research. 

Read the latest articles in the Neuroscience section

Introducing new sections to Journal of Translational Medicine!

Molecular Pathology

Led by Section Editor Sarah Warren, the Molecular Pathology section aims to highlight studies that characterize human-derived biological materials, including both tissue and liquid biopsies, using molecular profiling techniques to elucidate the underlying causes of disease and impacts of therapeutic interventions. 

The Molecular Pathology section will consider studies that are preclinical or translational in nature, as well as from all stages of fundamental and applied research. The section welcomes manuscripts that describe new technology platforms that advance molecular profiling or novel computational approaches to support data analysis.

Network Medicines

Led by Section Editor Joyce Hu, the Network Medicines section is dedicated to the biology-based, integrative approach aimed at understanding the topology of complex disorders and the dynamic interplay of their various components, identifying cascades of causes and effects, listening to cross-talks among cells to suggest novel and more effective therapeutic approaches.

The section welcomes research that goes beyond descriptive observations and provides compelling recommendations of disruptive therapeutic candidates.

Translational Process

© smolaw11 / stock.adobe.comLed by Marina Boccardi, the Translational Process section welcomes contributions aimed to streamline the transition of new knowledge along the translational continuum, and boost our ability to concretely innovate clinical practice. 

The Translational Process section dedicates a space to those who tackle such challenges overcoming the boundaries of individual disciplines, and offers a new opportunity to share and accelerate the development of urgently needed methods, tools and procedures. 

Reproductive Medicine & Clinical Reproductive Sciences

© Sebastian Kaulitzki / stock.adobe.comLed by Section Editor Matteo Alessandro Avella, the Reproductive Medicine & Clinical Reproductive Science section is focused on the basic mechanisms or the translational and clinical aspects of human reproductive biology. 

The section welcomes studies on preclinical and clinical studies whose results have the potential to prevent, diagnose, and treat reproductive issues, as well as studies that describe and characterize the genes and the mechanisms regulating human reproductive biology in cell line or animal models, and reviews on existing and novel technologies.

Editor-in-Chief: Francesco Marincola, Sonata Therapeutics, USA

Franco Marincola is the Chief Scientific Officer of Sonata Therapeutics. Franco brings over 30 years of research and development experience in immunology, oncology and cell therapy to Sonata.

Most recently, Franco served as Senior Vice President and Global Head of Research at Kite Pharma where he led the research organization to identify novel therapies for hematologic malignancies and solid tumors. Prior to Kite, he was President and Chief Scientific Officer at Refuge Biotechnologies, where he developed research strategies for adoptive cell therapy products and led therapeutic programs based on nuclease deactivated CRISPR circuits. Prior to Refuge, Franco was Distinguished Research Fellow in Immune Oncology at AbbVie, and Chief Research Officer at Sidra Medical and Research Centre.

Before joining the biopharma industry, Franco spent more than two decades at the National Institutes of Health (NIH) and National Cancer Institute (NCI), most recently as a tenured senior investigator in cancer immunotherapy and biomarker research and as Chief Infectious Disease and Immunogenetics Investigator at the NIH Clinical Center.

Franco is the former President of the Society for Immunotherapy of Cancer (SITC). He currently serves as Editor-in-Chief for multiple peer-reviewed publications, including Journal of Translational Medicine, Translational Medicine Communications, and Immunotherapy, and is the author of more than 600 peer-reviewed publications.

Franco received his M.D. from the University of Milan and completed his residency at Stanford University.

Aims and scope

Journal of Translational Medicine is an open access journal publishing articles focusing on information derived from human experimentation so as to optimise the communication between basic and clinical science.

The journal covers all areas of translational medicine but also has several special sections:

Annual Journal Metrics